Disease Progression

/Disease Progression

Standardizing PSA Definition of Biochemical Recurrence after Radical Prostatectomy

There are multiple definitions of biochemical recurrence for prostate cancer treatment post surgery. This causes confusion both within the patient community and the medical community. It would be very helpful if we could standardize a simple measure, PSA as the biomarker for a biochemical recurrence. Standardization post surgery would give us a better way to decide at what point additional treatment would most benefit a man with recurrent prostate cancer. To accomplish this goal researchers reviewed the long-term prostatectomy outcomes to assess the most appropriate prostate specific antigen cut point that predicts future disease progression. The study was large, including [...]

Real Life Issues About Abiraterone Acetate (Zytiga) Prior to Chemotherapy – Unanticipated Real-World Clinical Experience Worth Noting

Researchers in Hong Kong wanted to confirm the efficacy of abiraterone acetate (Zytiga) used prior to chemotherapy that had been shown in the trial setting. In their analysis they came up short; raising some very significant concerns about Zytiga’s efficacy when used prior to chemotherapy. They reviewed the clinical records of men with metastatic castrate resistant prostate cancer (mCRPC) who had been treated with Zytiga from all 6 public oncology centers in Hong Kong between August 2011 and December 2014. They evaluated their treatment efficacy, its determinants and toxicities. They evaluated 110 men with castrate resistant prostate cancer of whom [...]

Comparing (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) and (11)C-choline PET/CT in Prostate Cancer Relapse

There has been a lot of hype and confusion about what is the best contrast for prostate cancer PET/CT scans. The two newest contrasts; (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) and (11)C-choline both have their supporters and their detractors. To try and evaluate the efficacy differences between these two contrasts in men who have suffered a bio-chemical recurrence after surgery researchers did a head to head evaluation of 100 consecutive men treated with surgery for prostate cancer and presenting with a rising PSA. All of the men had (11)C-choline and (18)F-FACBC PET/CTs performed within 1 week and were off hormonal therapy at the time [...]

Why I Believe Xtandi Is Superior To Zytiga

I believe that Xtandi (enzalutamide) is a superior drug compared to Zytiga (abiraterone). Here's why. The phase III trials for both Xtandi and Zytiga were very similar to each other. In both trials investigators measured the percentage of men who progressed or died against placebo. In this very important measurement Xtandi blew Zytiga out of the water. Only 14% of men taking Xtandi during the trial progressed or died compared to 40% of the men in the placebo group. In the phase III trial of Zytiga 28% of the men progressed or died, compared with 46% on placebo. This figure is very [...]